前列腺癌筛查中的磁共振成像:系统综述与荟萃分析
该系统综述与荟萃分析纳入12项研究共80114名男性,比较基于MRI的筛查路径与单纯PSA筛查联合系统活检的诊断价值。结果显示,序贯MRI筛查(PI-RADS≥3分作为活检指征)在维持临床显著前列腺癌检出率的同时,减少不必要的活检和临床不显著前列腺癌的检出。
要点
- 与单纯PSA筛查相比,序贯MRI路径(PI-RADS≥3分活检)临床显著前列腺癌检出无显著差异(OR 1.02)。
- 序贯MRI路径活检几率降低(OR 0.28),临床不显著前列腺癌检出几率降低(OR 0.34)。
- 以PI-RADS≥4分为活检阈值进一步降低不显著前列腺癌检出(OR 0.23)和活检几率(OR 0.19)。
核心结论
- 该系统综述与荟萃分析提示,在前列腺癌筛查路径中整合MRI与减少不必要的活检和临床不显著前列腺癌的过度诊断相关,同时维持临床显著前列腺癌的检出。
研究设计与样本
- 系统综述与荟萃分析,检索PubMed/MEDLINE、Embase、Cochrane/Central、Scopus和Web of Science(截至2023年5月)。
- 纳入报告前列腺MRI在前列腺癌筛查中诊断效用的随机临床试验和前瞻性队列研究。
- 共纳入12项研究、80114名男性,提取筛查人数、活检指征、活检次数、临床显著前列腺癌(ISUP分级≥2)和临床不显著前列腺癌(ISUP 1)检出数。
主要发现
- 与标准PSA筛查相比,序贯MRI筛查(PI-RADS≥3分为活检指征)在检测结果阳性时临床显著前列腺癌检出几率更高(OR 4.15;95%CI 2.93-5.88;P≤.001)。
- 序贯MRI筛查(PI-RADS≥3分)活检几率降低(OR 0.28;95%CI 0.22-0.36;P≤.001),临床不显著前列腺癌检出几率降低(OR 0.34;95%CI 0.23-0.49;P=.002)。
- 序贯MRI筛查(PI-RADS≥3分)临床显著前列腺癌检出无显著差异(OR 1.02;95%CI 0.75-1.37;P=.86)。
- 以PI-RADS≥4分为活检阈值时,临床不显著前列腺癌检出几率进一步降低(OR 0.23;95%CI 0.05-0.97;P=.048),活检几率降低(OR 0.19;95%CI 0.09-0.38;P=.01),临床显著前列腺癌检出无差异(OR 0.85;95%CI 0.49-1.45;P=.22)。
关键数值与推荐
- 临床显著前列腺癌定义为国际泌尿病理学会(ISUP)分级≥2,临床不显著前列腺癌定义为ISUP 1。
- 活检指征采用前列腺影像报告和数据系统(PI-RADS)评分≥3分或≥4分。
- 采用广义混合效应方法,合并比值比(OR)和随机效应模型比较基于MRI与单纯PSA的筛查策略。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Prostate magnetic resonance imaging (MRI) is increasingly integrated within the prostate cancer (PCa) early detection pathway. OBJECTIVE: To systematically evaluate the existing evidence regarding screening pathways incorporating MRI with targeted biopsy and assess their diagnostic value compared with prostate-specific antigen (PSA)-based screening with systematic biopsy strategies. DATA SOURCES: PubMed/MEDLINE, Embase, Cochrane/Central, Scopus, and Web of Science (through May 2023). STUDY SELECTION: Randomized clinical trials and prospective cohort studies were eligible if they reported data on the diagnostic utility of prostate MRI in the setting of PCa screening. DATA EXTRACTION: Number of screened individuals, biopsy indications, biopsies performed, clinically significant PCa (csPCa) defined as International Society of Urological Pathology (ISUP) grade 2 or higher, and insignificant (ISUP1) PCas detected were extracted. MAIN OUTCOMES AND MEASURES: The primary outcome was csPCa detection rate. Secondary outcomes included clinical insignificant PCa detection rate, biopsy indication rates, and the positive predictive value for the detection of csPCa. DATA SYNTHESIS: The generalized mixed-effect approach with pooled odds ratios (ORs) and random-effect models was used to compare the MRI-based and PSA-only screening strategies. Separate analyses were performed based on the timing of MRI (primary/sequential after a PSA test) and cutoff (Prostate Imaging Reporting and Data System [PI-RADS] score ≥3 or ≥4) for biopsy indication. RESULTS: Data were synthesized from 80 114 men from 12 studies. Compared with standard PSA-based screening, the MRI pathway (sequential screening, PI-RADS score ≥3 cutoff for biopsy) was associated with higher odds of csPCa when tests results were positive (OR, 4.15; 95% CI, 2.93-5.88; P ≤ .001), decreased odds of biopsies (OR, 0.28; 95% CI, 0.22-0.36; P ≤ .001), and insignificant cancers detected (OR, 0.34; 95% CI, 0.23-0.49; P = .002) without significant differences in the detection of csPCa (OR, 1.02; 95% CI, 0.75-1.37; P = .86). Implementing a PI-RADS score of 4 or greater threshold for biopsy selection was associated with a further reduction in the odds of detecting insignificant PCa (OR, 0.23; 95% CI, 0.05-0.97; P = .048) and biopsies performed (OR, 0.19; 95% CI, 0.09-0.38; P = .01) without differences in csPCa detection (OR, 0.85; 95% CI, 0.49-1.45; P = .22). CONCLUSION AND RELEVANCE: The results of this systematic review and meta-analysis suggest that integrating MRI in PCa screening pathways is associated with a reduced number of unnecessary biopsies and overdiagnosis of insignificant PCa while maintaining csPCa detection as compared with PSA-only screening.
引用
- Fazekas T, Shim SR, Basile G, et al. Magnetic Resonance Imaging in Prostate Cancer Screening: A Systematic Review and Meta-Analysis. JAMA Oncol. 2024. PMID: 38576242. doi:10.1001/jamaoncol.2024.0734
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。